@Caleb_Crann Both $HELP and Usona are targeting MDD. Good luck with prior authorization for an indication that has dozens of approved treatments. I can't even get simple medication approved at the pharmacy but I am sure providers will be eager to foot the bill for multiple hour treatments.
@Psyched_Alpha I thought you said this was a neck to neck race. Raison replaced Ramey almost a month ago. Raison has given a couple of interviews since the EO and voucher award saying he expects Compass to be approved first. Never once insinuated there was a race.
@ScienceWhats@B__Digs@Charles70563640 Good luck with the prior authorization roadblock that any therapy targeting MDD is going to face. There is a reason why $CMPS and $ATAI are targeting TRD and $DFTX targeting GAD. Unmet need.
@ScienceWhats@B__Digs@Charles70563640 As far as rescheduling, trigger laws in many states are specific to a crystalline polymorph of Psilocybin. $HELP is going to have to do lobbying of their own.
@ScienceWhats@B__Digs@Charles70563640 $HELP is targeting MDD as an adjunct therapy. Also, what are you on about REMS lol. FDA has consistently told $CMPS that REMS will be similar to Spravato.
@katrosenfield@edavidds@Timodc If you believe what is happening today is not vastly more destructive, then you are as partisan as the people who fawn over the bad bunny HT show.
@katrosenfield You work for FP that has advocated withholding funding to universities in its editorial pages. I would say they have far more utilitarian value to society than a performing center.
@Caleb_Crann@Zetaboy69@DrAdamBorecky The number of patients you can dose vs number of patients actually being dosed in a daily schedule in these centers is something most modelers are ignoring. People are treating this like an optimization problem with constrained capacity which is simply not the case.
@JSpitTrades His buddies have already exhausted the bond market and private credit markets. They now need a jacked up equity market to keep up with the cost of capital with ATM offerings.